Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Summary of findings: Comparison 5 ‐ deferiprone (DFP) plus deferoxamine (DFO) vs DFP QoL Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Comparison 6 ‐ deferiprone (DFP) plus deferoxamine (DFO) vs DFO All‐cause mortality Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Comparison 6 ‐ deferiprone (DFP) plus deferoxamine (DFO) vs DFO Sustained adherence Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Comparison 6 ‐ deferiprone (DFP) plus deferoxamine (DFO) vs DFO QoL Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Comparison 7 ‐ deferiprone (DFP) plus deferoxamine (DFO) vs DFP plus deferasirox (DFX) Sustained adherence Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Comparison 8 ‐ medication management vs standard care Adherence to iron chelation Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Comparison 8 ‐ medication management vs standard care SAEs Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Comparison 1 ‐ deferiprone (DFP) vs deferoxamine (DFO) Sustained adherence Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Comparison 8 ‐ medication management vs standard care Mortality Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Comparison 8 ‐ medication management vs standard care Sustained adherence Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or… (2023) · Cochrane | no estimate extracted | NR | No studies |
Angiotensin‐converting enzyme inhibitors vs vitamin C Serious adverse events · children with sickle cell anaemia and microalbuminuria Interventions for chronic kidney disease in people with sickle cell disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Angiotensin‐converting enzyme inhibitors vs vitamin C Mortality due to any cause · children with sickle cell anaemia and microalbuminuria Interventions for chronic kidney disease in people with sickle cell disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Angiotensin‐converting enzyme inhibitors vs vitamin C Quality of life · children with sickle cell anaemia and microalbuminuria Interventions for chronic kidney disease in people with sickle cell disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Hydroxyurea vs placebo Quality of life · people with sickle cell disease Interventions for chronic kidney disease in people with sickle cell disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Angiotensin‐converting enzyme inhibitors vs placebo Serious adverse events · people with sickle cell disease Interventions for chronic kidney disease in people with sickle cell disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Angiotensin‐converting enzyme inhibitors vs placebo All‐cause mortality · people with sickle cell disease Interventions for chronic kidney disease in people with sickle cell disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Angiotensin‐converting enzyme inhibitors vs placebo Quality of life · people with sickle cell disease Interventions for chronic kidney disease in people with sickle cell disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Medical vs open surgical PD catheter insertion Technique failure · improving catheter function and clinical outcomes in PD patients Catheter insertion techniques for improving catheter function and clinical outcomes in peritoneal dialysis… (2023) · Cochrane | no estimate extracted | NR | No studies |
Percutaneous vs open surgical PD catheter insertion Long‐term PD catheter failure (> 4 weeks following PD catheter insertion) · improving catheter function and clinical outcomes in PD patients Catheter insertion techniques for improving catheter function and clinical outcomes in peritoneal dialysis… (2023) · Cochrane | no estimate extracted | NR | No studies |
Percutaneous vs open surgical PD catheter insertion Technique failure · improving catheter function and clinical outcomes in PD patients Catheter insertion techniques for improving catheter function and clinical outcomes in peritoneal dialysis… (2023) · Cochrane | no estimate extracted | NR | No studies |
Peritoneoscopic vs open surgical PD catheter insertion Technique failure · improving catheter function and clinical outcomes in PD patients Catheter insertion techniques for improving catheter function and clinical outcomes in peritoneal dialysis… (2023) · Cochrane | no estimate extracted | NR | No studies |
Laparoscopic vs open surgical PD catheter insertion Technique failure · patients requiring PD catheter placement Catheter insertion techniques for improving catheter function and clinical outcomes in peritoneal dialysis… (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Resource use or economic outcomes during hospital stay · health professionals providing care to patients with stroke Interventions for the uptake of evidence‐based recommendations in acute stroke settings (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Health professional knowledge at 90 d · health professionals providing care to patients with stroke Interventions for the uptake of evidence‐based recommendations in acute stroke settings (2023) · Cochrane | no estimate extracted | NR | No studies |
Infliximab 5 mg/kg vs infliximab 10 mg/kg Withdrawals due to adverse events · active Crohn's disease Infliximab for medical induction of remission in Crohn's disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Infliximab 5 mg/kg vs infliximab 20 mg/kg Withdrawals due to adverse events · active Crohn's disease Infliximab for medical induction of remission in Crohn's disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Infliximab 10 mg/kg vs infliximab 20 mg/kg Withdrawals due to adverse events · active Crohn's disease Infliximab for medical induction of remission in Crohn's disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Infliximab 5–10 mg/kg vs placebo Withdrawals due to adverse events · active Crohn's disease Infliximab for medical induction of remission in Crohn's disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Trifocal intraocular lenses vs bifocal intraocular lenses after cataract extraction among participants with presbyopia Mean contrast sensitivity (1 year) · people (> 30 years) with cataract and presbyopia Trifocal intraocular lenses versus bifocal intraocular lenses after cataract extraction among participants… (2023) · Cochrane | no estimate extracted | NR | No studies |
Trifocal intraocular lenses vs bifocal intraocular lenses after cataract extraction among participants with presbyopia Mean quality of life or visual function (measured using Visual Function Index‐14 tool) (1 year) · people (> 30 years) with cataract and presbyopia Trifocal intraocular lenses versus bifocal intraocular lenses after cataract extraction among participants… (2023) · Cochrane | no estimate extracted | NR | No studies |
Vitamin D vs placebo Quality of life · premenopausal women (age 18–32.7 years) Calcium and vitamin D for increasing bone mineral density in premenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Vitamin D vs placebo Vertebral fracture · premenopausal women (age 18–32.7 years) Calcium and vitamin D for increasing bone mineral density in premenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Vitamin D vs placebo Non‐vertebral fracture · premenopausal women (age 18–32.7 years) Calcium and vitamin D for increasing bone mineral density in premenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Vitamin D vs placebo Serious adverse events · premenopausal women (age 18–32.7 years) Calcium and vitamin D for increasing bone mineral density in premenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Calcium and vitamin D vs placebo Quality of life · premenopausal women (ages 18–36 years) Calcium and vitamin D for increasing bone mineral density in premenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Calcium and vitamin D vs placebo Vertebral fracture · premenopausal women (ages 18–36 years) Calcium and vitamin D for increasing bone mineral density in premenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Calcium and vitamin D vs placebo Non‐vertebral fracture · premenopausal women (ages 18–36 years) Calcium and vitamin D for increasing bone mineral density in premenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Calcium and vitamin D vs placebo Serious adverse events · premenopausal women (ages 18–36 years) Calcium and vitamin D for increasing bone mineral density in premenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Calcium vs placebo Quality of life · premenopausal women (age 18−47.3 years) Calcium and vitamin D for increasing bone mineral density in premenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Calcium vs placebo Vertebral fracture · premenopausal women (age 18−47.3 years) Calcium and vitamin D for increasing bone mineral density in premenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Calcium vs placebo Non‐vertebral fracture · premenopausal women (age 18−47.3 years) Calcium and vitamin D for increasing bone mineral density in premenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Calcium vs placebo Serious adverse events · premenopausal women (age 18−47.3 years) Calcium and vitamin D for increasing bone mineral density in premenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Vitamin D vs placebo Total hip BMD · premenopausal women (age 18–32.7 years) Calcium and vitamin D for increasing bone mineral density in premenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Vitamin D vs placebo Lumbar spine BMD · premenopausal women (age 18–32.7 years) Calcium and vitamin D for increasing bone mineral density in premenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Magnetic seizure therapy plus standard care vs electroconvulsive therapy plus standard care Cognitive functioning: clinically important change ‐ not measured · people with acute schizophrenia Magnetic seizure therapy for people with schizophrenia (2023) · Cochrane | no estimate extracted | NR | No studies |
Magnetic seizure therapy plus standard care vs electroconvulsive therapy plus standard care Quality of life: clinically important change ‐ not measured · people with acute schizophrenia Magnetic seizure therapy for people with schizophrenia (2023) · Cochrane | no estimate extracted | NR | No studies |
Magnetic seizure therapy plus standard care vs electroconvulsive therapy plus standard care Social functioning: clinically important change ‐ not measured · people with acute schizophrenia Magnetic seizure therapy for people with schizophrenia (2023) · Cochrane | no estimate extracted | NR | No studies |
Personalised intervention vs non‐personalised intervention Any adverse events · subgroups of children with conduct problems Personalised interventions for subgroups of children with conduct problems (2023) · Cochrane | no estimate extracted | NR | No studies |
Personalised intervention vs non‐personalised intervention Personalised treatment outcomes, relevant to each subgroup · subgroups of children with conduct problems Personalised interventions for subgroups of children with conduct problems (2023) · Cochrane | no estimate extracted | NR | No studies |
Personalised intervention vs non‐personalised intervention Parenting skills and knowledge · subgroups of children with conduct problems Personalised interventions for subgroups of children with conduct problems (2023) · Cochrane | no estimate extracted | NR | No studies |